FTC To Probe Impact Of PBMs On Consumer Drug Costs

By John Wilkerson / June 7, 2022 at 4:21 PM
The Federal Trade Commission voted Monday (June 6) to study the impact of pharmacy benefit managers’ business practices on consumer drug costs, requiring the six largest PBMs to provide information and records regarding their business practices. FTC narrowly voted against a similar study in February, but since then the Senate confirmed an additional Democratic-nominated commissioner and the two Republicans who blocked the probe last time voted for the study this time because, they said, it has been improved. “[S]omething is...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.